These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 31284669)
1. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model. Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669 [TBL] [Abstract][Full Text] [Related]
2. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway. Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489 [TBL] [Abstract][Full Text] [Related]
3. Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma. Yang MH; Jung SH; Chinnathambi A; Alahmadi TA; Alharbi SA; Sethi G; Ahn KS Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878046 [TBL] [Abstract][Full Text] [Related]
4. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356 [TBL] [Abstract][Full Text] [Related]
5. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib. Zhao Y; Zhang K; Li G; Zhang X; Shi D PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846 [TBL] [Abstract][Full Text] [Related]
6. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism]. Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142 [TBL] [Abstract][Full Text] [Related]
7. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma. Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537 [TBL] [Abstract][Full Text] [Related]
8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Que W; Chen J; Chuang M; Jiang D APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676 [TBL] [Abstract][Full Text] [Related]
9. Fangchinoline, a Bisbenzylisoquinoline Alkaloid can Modulate Cytokine-Impelled Apoptosis via the Dual Regulation of NF-κB and AP-1 Pathways. Jung YY; Shanmugam MK; Chinnathambi A; Alharbi SA; Shair OHM; Um JY; Sethi G; Ahn KS Molecules; 2019 Aug; 24(17):. PubMed ID: 31466313 [TBL] [Abstract][Full Text] [Related]
10. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569 [TBL] [Abstract][Full Text] [Related]
11. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma. Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118 [TBL] [Abstract][Full Text] [Related]
12. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469 [TBL] [Abstract][Full Text] [Related]
13. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Yang M; Huang J; Pan HZ; Jin J Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856 [TBL] [Abstract][Full Text] [Related]
14. Ophiopogonin D modulates multiple oncogenic signaling pathways, leading to suppression of proliferation and chemosensitization of human lung cancer cells. Lee JH; Kim C; Lee SG; Yang WM; Um JY; Sethi G; Ahn KS Phytomedicine; 2018 Feb; 40():165-175. PubMed ID: 29496169 [TBL] [Abstract][Full Text] [Related]
15. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454 [TBL] [Abstract][Full Text] [Related]
16. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
17. Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. Kim C; Lee SG; Yang WM; Arfuso F; Um JY; Kumar AP; Bian J; Sethi G; Ahn KS Cancer Lett; 2018 Sep; 431():123-141. PubMed ID: 29857127 [TBL] [Abstract][Full Text] [Related]
18. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells. Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823 [TBL] [Abstract][Full Text] [Related]
19. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656 [TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]